Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities
The tumor immune microenvironment represents a sophisticated ecosystem where various
immune cell subtypes communicate with cancer cells and stromal cells. The dynamic …
immune cell subtypes communicate with cancer cells and stromal cells. The dynamic …
How metabolism bridles cytotoxic CD8+ T cells through epigenetic modifications
HH Van Acker, S Ma, T Scolaro, SM Kaech… - Trends in …, 2021 - cell.com
In the direct competition for metabolic resources between cancer cells and tumor-infiltrating
CD8+ T cells, the latter are bound to lose out. These effector lymphocytes are therefore …
CD8+ T cells, the latter are bound to lose out. These effector lymphocytes are therefore …
Bromodomain protein BRD4 directs and sustains CD8 T cell differentiation during infection
In response to infection, pathogen-specific CD8 T cells differentiate into functionally diverse
effector and memory T cell populations critical for resolving disease and providing durable …
effector and memory T cell populations critical for resolving disease and providing durable …
Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy
N Principe, J Kidman, S Goh, CM Tilsed… - Frontiers in …, 2020 - frontiersin.org
Immune checkpoint therapy (ICT) results in durable responses in individuals with some
cancers, but not all patients respond to treatment. ICT improves CD8+ cytotoxic T …
cancers, but not all patients respond to treatment. ICT improves CD8+ cytotoxic T …
In vitro and in vivo evaluation of immune response of poly (lactic acid) nanoparticles with different end groups
Y Gao, J Yang, Y Zhang, Y Zhao, X Zhao… - International Journal of …, 2023 - Elsevier
Abstract Poly (lactic acid)(PLA) has excellent properties of biodegradability and
biocompatibility, which is a US Food and Drug Administration (FDA) approved biopolymer …
biocompatibility, which is a US Food and Drug Administration (FDA) approved biopolymer …
Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma
Targeted therapy and immunotherapy have revolutionized the treatment of metastatic skin
melanoma but around half of all patients develop resistance early or late during treatment …
melanoma but around half of all patients develop resistance early or late during treatment …
Regulation and immunotherapeutic targeting of the epigenome in exhausted CD8 T cell responses
BR Ford, AC Poholek - The Journal of Immunology, 2023 - journals.aai.org
Exhaustion is a state of CD8 T cell differentiation that occurs in settings of chronic Ag such
as tumors, chronic viral infection, and autoimmunity. Cellular differentiation is driven by a …
as tumors, chronic viral infection, and autoimmunity. Cellular differentiation is driven by a …
Tumor Antigen-Specific Infiltrating CD8+ Effector T Cells Memory Predict Response to Immune Checkpoint Therapy
N Principe, J Kidman, S Goh, CM Tilsed… - … of Response to Anti …, 2021 - books.google.com
Principe N, Kidman J, Goh S, Tilsed CM, Fisher SA, Fear VS, Forbes CA, Zemek RM, Chopra
A, Watson M, Dick IM, Boon L, Holt RA, Lake RA, Nowak AK, Lesterhuis WJ, McDonnell AM …
A, Watson M, Dick IM, Boon L, Holt RA, Lake RA, Nowak AK, Lesterhuis WJ, McDonnell AM …
Phenotypic and functional characterisation of circulating cytomegalovirus-specific T cells in healthy virus carriers and lung transplant candidates
M Altaf, MA Irfan, N Naheed, NM Aleemuddin - medRxiv, 2021 - medrxiv.org
Background Deficiencies in CMV-specific T cell immunity pre-transplant increase patient risk
of CMV reactivation and disease post-transplantation. The aim of this study was to …
of CMV reactivation and disease post-transplantation. The aim of this study was to …
Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in uveal melanoma
Targeted therapy and immunotherapy have revolutionized the treatment of metastatic skin
melanoma but none of the treatments are approved for patients with metastatic uveal …
melanoma but none of the treatments are approved for patients with metastatic uveal …